AC
VYGR icon

Ascend Capital’s Voyager Therapeutics VYGR Stock Holding History

Ascend Capital’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-58,267
Closed -$700K – 174
2016
Q3 		$700K Buy
+58,267
New +$789K 0.04% 112

Other funds holding VYGR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Ascend Capital's VYGR Position: Q4 2016 in Review

Ascend Capital sold out of Voyager Therapeutics (VYGR) in Q4 2016, closing a stake of 58,267 shares — an estimated $700K sold.

Ascend Capital first reported a position in VYGR in Q3 2016 and held it in 1 quarter. The position peaked at $700K in Q3 2016. 56 funds tracked by Wall St. Rank hold VYGR as of Q4 2016.

  • Ascend Capital reported no remaining Voyager Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Ascend Capital sold 58,267 Voyager Therapeutics shares in Q4 2016, an estimated $700K.
  • Ascend Capital first reported a position in Voyager Therapeutics in Q3 2016 and held it in 1 quarter.
  • Ascend Capital's Voyager Therapeutics position peaked at $700K in Q3 2016.
  • 56 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q4 2016.

Based on Ascend Capital's 13F filing for Q4 2016, filed 13 Feb 2017.